# WIRE - Novel Treatments in Renal Cell Cancer

> **NCT03741426** · PHASE2 · UNKNOWN · sponsor: **CCTU- Cancer Theme** · enrollment: 60 (estimated)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Cediranib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03741426
- **Lead sponsor:** CCTU- Cancer Theme
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-27
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-06-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03741426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03741426, "WIRE - Novel Treatments in Renal Cell Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03741426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*